Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study

Table 3

Univariate and multivariate analysis of PFS in patients treated with immune checkpoint inhibitors.

Baseline characteristics	Median PFS (95% CI)	value (univariate analysis)	HR (95% CI)	value (multivariate analysis)
Ages (years)		0.250
<65	13.20 (9.173–17.227)
≥65	14.80 (10.526–19.074)
Sex		0.224
Male	12.10 (7.401–16.799)
Female	16.20 (13.223–19.177)
Therapy lines		0.096
First-line	15.10 (14.567–15.633)		0.604 (0.383–0.955)	0.031
Second or more-line	8.60 (5.248–11.952)
Smoking history		0.010
Never-smoker	15.40 (14.114–16.686)		1.976 (1.247–3.133)	0.004
Current or ex-smoker	8.60 (4.161–13.039)
Histology		0.688
Nonsquamous	13.20 (9.001–17.399)
Squamous	14.10 (11.276–16.924)
Pathological staging		0.323
III	6.60 (0.000–13.417)
IV	14.10 (11.589–16.611)
Presence of treating with antibiotic during immunotherapy		0.754
Yes	11.20 (6.271–16.129)
No	14.70 (10.299–19.101)
Presence of serious AEs		0.749
Yes	11.20 (2.929–19.471)
No	14.10 (10.882–17.318)
Presence of irAEs		0.504
Yes	15.40 (10.657–17.143)
No	13.20 (10.191–16.209)